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Abstract
The urgent need to expand the donor pool in order to 
attend to the growing demand for liver transplantation 
has obliged physicians to consider the use of suboptimal 
liver grafts and also to redefine the preservation 
strategies. This review examines the different methods 
of liver graft preservation, focusing on the latest 
advances in both static cold storage and machine 
perfusion (MP). The new strategies for static cold 
storage are mainly designed to increase the fatty 
liver graft preservation via  the supplementation of 
commercial organ preservation solutions with additives. 
In this paper we stress the importance of carrying out 
effective graft washout after static cold preservation, and 
present a detailed discussion of the future perspectives 
for dynamic graft preservation using MP at different 
temperatures (hypothermia at 4 ℃, normothermia 
at 37 ℃ and subnormothermia at 20 ℃-25 ℃). 
Finally, we highlight some emerging applications of 
regenerative medicine in liver graft preservation. In 
conclusion, this review discusses the “state of the art” 
and future perspectives in static and dynamic liver graft 
preservation in order to improve graft viability. 
Key words: Static cold preservation; Suboptimal liver 
grafts; Preservation solutions; Graft washout solutions; 
Machine perfusion and liver bioengineering
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Core tip: This review focuses on the latest advances in 
liver graft preservation, in both static cold storage and 
dynamic preservation by machine perfusion (MP). We 
describe some new trends for static cold preservation 
based on our experience; we stress the importance of 
developing washout solutions and the use of MP for 
suboptimal liver grafts. Finally, we discuss emerging 
applications of regenerative medicine in liver graft 
preservation. 
function of  the organ and tissue during storage so 
that the graft will be viable at reperfusion. To date, 
the predominant organ preservation method used by 
most centers is SCS. The principles of  SCS are based 
on the diminution of  metabolism by hypothermia. The 
appropriate preservation solution is infused into the 
organ (the cooling phase) and then stored statically[4]. 
Cooling
SCS is the most widely used method for preserving 
organs for transplantation. Cooling is necessary to reduce 
cellular metabolism and the oxygen requirements in order 
to prevent tissue injury[5]. 
In order to obtain viable organs after long-term 
preservation, various methods have been proposed, 
ranging from organ freezing and vitrification[6,7] to 
“supercooling” (subzero non-freezing at 0 ℃ to -5 ℃)[8-11]. 
In general, long-term survival rates after transplantaion 
using these methods are disappointing. 
However, in a recent study by Berendsen et al[12], 
the combination of  “supercooling” (cold preservation 
at -6 ℃) with other parameters achieved effective 
preservation of  liver grafts for 4 d. This promising new 
technique comprises three steps: first, “supercooling” 
of  the organ at -6 ℃ to reduce the cellular metabolism; 
second, subnormothermic mp at 21 ℃ (see the 
dynamic preservation section below), which reinitiates 
the metabolism and replenishes ATp levels, and third, 
the use of  two preservatives, 3-O-methyl-D-glucose 
(3-OmG) and polyethylene-glycol 35 (pEG35). Each 
of  these conditions is necessary to achieve successful 
liver transplantation[13]. With this in mind, supercooling 
techniques may be a potentially useful tool for suboptimal 
livers which are currently discarded for transplantation 
purposes, and may have great impact on global organ 
sharing.
Preservation solutions
Although cold is a fundamental requirement for tissue 
preservation, it has harmful repercussions due to the 
induction of  cell swelling[14] and cytoskeletal alteration[15]. 
This was in part the reason for the development of commercial 
organ preservation solutions able to prevent many of  the 
cellular alterations associated with hypothermia and to 
mitigate the harmful effects of  cooling. 
Euro-Collins (EC) solution was developed in the 
1970s as a high potassium-sodium solution (intracellular 
composition) which does not contain oncotic agents but 
does contain glucose. Given that glucose is impermeable 
to renal cells, this preservation solution was suitable 
for kidney preservation when relatively short times 
were needed or DCD organs were used. However, the 
permeability of  the liver and pancreatic cells to glucose 
leads to the loss of  the osmotic effect, and also causes the 
subsequent anaerobic metabolization of  glucose, inducing 
intracellular acidosis and thus limiting cell preservation. 
This is why glucose was later substituted by other larger 
sugar molecules such as lactobionate and raffinose in 
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INTRODUCTION
Liver transplantation is the definitive treatment option 
for end-stage liver diseases. Besides the immunological 
mechanisms of  graft rejection, liver transplantation 
outcome is also limited by ischemia-reperfusion injury 
(IRI). IRI is a complex multifactorial process caused, 
principally, by the energy depletion during graft cold 
storage in preservation solutions (cold ischemia) and 
the subsequent production of  oxidative stress and 
inflammatory events after graft revascularization in the 
recipient (reperfusion)[1]. IRI is associated with delayed 
graft function and primary graft failure, which remains 
one of  the major clinical problems following liver 
transplantation.
A common strategy to reduce ischemic injury follo-
wing explantation from the donor is the rapid cooling 
of  the organs with the use of  a preservation solution 
to minimize enzymatic activity and energy substrate 
depletion. In recent decades, major advances have been 
made in the area of  liver preservation, including the 
development of  new preservation solutions. Their emer-
gence has helped to decrease hypoxic injury and has 
reduced graft vulnerability against reperfusion insult. 
Currently, the high increase in demand for organs 
has obliged physicians to use suboptimal grafts in 
order to increase the organ supply for transplantation. 
Suboptimal or extended criteria donor (ECD) livers 
include organs characterized by steatosis, old donor 
age, prolonged cold ischemia or donation after cardiac 
death (DCD)[2,3]. It is well known that suboptimal livers 
present increased vulnerability to IRI, and are associated 
with graft dysfunction and long-term survival problems 
after surgery. For this reason, preservation methods for 
suboptimal livers need to be exhaustively explored in 
order to identify the ones that are the most suitable for 
graft conservation.
machine perfusion (mp) has emerged as an alternative 
preservation strategy to static cold storage (SCS). mp is 
already routinely used for kidney transplantation, but a 
great deal is still to be done before it can be regularly used 
in clinical liver transplantation. In this review, we examine 
the SCS and mp techniques in detail, describing the latest 
advances in the development of  preservation solutions 
for liver grafts and providing some proposals and new 
strategies in order to improve current graft preservation 
methods. 
STATIC COLD STORAGE
The main goal in organ preservation is to maintain 
University of  Wisconsin (UW) solution, which remains in 
the extracellular space and preserves its beneficial effect. 
The use of  the UW preservation solution improved organ 
preservation time from 6 to 16 h[16]. 
The efficacy of  UW solution is based on the pre-
vention of  edema by impermeants (raffinose, lacto-
bionate), and the addition of  an ATp precursor (adeno-
sine) and anti-oxidant components (allopurinol, reduced 
glutathione). Drawbacks include the presence of  
hydroxyethyl starch (HES) as oncotic support, which has 
been associated with high blood viscosity and consequent 
tissue saturation with the preservation solution. As a 
result, washout of  blood from the graft and blood flow 
during reperfusion may be reduced[17,18]. In addition, 
the high K+ concentration is associated with cellular 
depolarization and activation of  voltage-dependent 
channels[19]. The problems caused by HES and K+ led to 
the development of  other preservation solutions without 
oncotic agents such as Celsior and HTK (Custodiol) 
and others with pEG as oncotic agent, such as Institute 
Georges Lopez solution (IGL-1) and Tissue and Organ 
Conservation Solution (SCOT).
Celsior was developed initially in the 1990s as a 
cardiac preservation solution with a low potassium 
and high sodium composition. Due to its extracellular 
composition, Celsior was also adopted for the preser-
vation of  abdominal organs as an alternative to UW. 
Other solutions without oncotic agents such as histidine-
tryptophan-ketoglutarate solution (HTK) were also 
developed. HTK presents low viscosity and for this 
reason provides more rapid cooling and better washout 
of  blood elements during organ procurement than UW. 
Celsior and HTK solutions have been extensively used 
for liver transplantation[20-22]. However, some limitations 
for HTK use have recently been described. Stewart et 
al[23] reported that HTK is associated with reduced graft 
survival in case of  additional risk factors such as DCD, 
cold ischemia time over 8 h, and donors over 70 years 
when compared to UW solution.
In IGL-1 preservation solution, HES was substituted 
by a pEG with a molecular weight of  35 KDa (pEG35), 
and the high K+/low Na+ ratio was reversed. Both 
experimental[24,25] and clinical[26-28] studies of  liver and 
kidney transplantation have shown the beneficial effects 
of  IGL-1 against apoptosis, endoplasmic reticulum stress, 
microcirculation dysfunction and immune response. 
moreover, in previous studies of  cold preservation and ex 
vivo perfusion, we have reported that IGL-1 contributes 
to a more efficient preservation of  both non-steatotic 
and steatotic rat liver grafts compared to UW[29-31], The 
beneficial effects of  IGL-1 include prevention of  hepatic 
damage, oxidative stress and mitochondrial injury, and 
are mediated through nitric oxide (NO) production. So 
IGL-1 is the first solution reported to be advantageous in 
SCS of  suboptimal livers.
moreover, a pEG of  smaller size, pEG20, is the basic 
component of  another solution for organ preservation: 
the SCOT, which furthermore contains low K+/high Na+ 
concentrations. SCOT was reported to show a higher 
renal protection against the immune response, mainly 
due to the “immunocamouflage” process provided 
by pEG20[32]. pEG20 at 15 g/L has been found to 
reduce alloantigen recognition after liver reperfusion 
in comparison to UW solution[33]. Even so, the use of  
pEG35 as oncotic agent has been shown to be more 
effective than pEG20 for liver graft preservation[34].
Modification of static preservation solutions
The extended use of  commercial preservation solutions 
has improved the conditions of  liver graft preservation, 
but with the increasing use of  suboptimal grafts it 
seems necessary to explore new alternatives in order to 
prolong the ischemia times and increase graft quality 
during cold storage. Along these lines, new additives have 
been proposed to improve static liver graft preservation 
when UW and IGL-1 solutions are used (Table 1). 
Although these alternatives are promising and have been 
successfully applied in animal models, they require further 
investigation before they can be implemented in clinical 
transplantation. 
Anti-ischemic drugs: previous work in kidney[35,36], 
liver[37,38] and heart[39-41] models has demonstrated the 
anti-oxidant action of  trimetazidine (TmZ), an anti-
ischemic drug. The addition of  TmZ to UW solution 
was tested in both steatotic and non-steatotic rat livers 
after cold storage and ex vivo perfusion[25]. The enrichment 
of  UW solution with TmZ reduced hepatic injury by 
diminishing microcirculatory dysfunction, oxidative stress, 
and mitochondrial damage. In the same experimental 
conditions, supplementation of  IGL-1 solution with 
TmZ offered better liver graft preservation than IGL-1 
solution alone and induced significant activation of  
hypoxia inducible factor-1α (HIF1α) and increased NO 
production[30]. The benefits of  TmZ have been shown 
clinically in patients undergoing hepatic surgery under 
vascular clamping[42]. This would suggest that TmZ has 
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Table 1  Additives for improving static cold storage in 
University of Wisconsin and Institute Georges Lopez preser-
vation solutions
Additive Preservation solution Ref.
TMZ UW, IGL-1 [25,30]
EGF + IGF-1 UW [45]
IGF-1 IGL-1 [44]
EGF IGL-1 [46]
ML IGL-1 [43]
BZ UW, IGL-1 [51,117]
SV UW [64]
BZ, MG132 UW [50]
ML + TMZ IGL-1 [38]
CAII IGL-1 [54]
TMZ: Trimetazidine; EGF: Endothelial growth factor; IGF: Insulin growth 
factor 1; ML: Melatonin; BZ: Bortezomib; SV: Simvastatin; CAII: Carbonic 
anhydrase Ⅱ; UW: University of Wisconsin; IGL-1: Institute Georges 
Lopez.
Bejaoui M et al . Emerging concepts in liver graft preservation
we have observed that fatty livers preserved in IGL-1 
solution supplemented with CAⅡ showed lower injury, 
better function and major reductions in liver apoptosis 
parameters[54]. So CA enrichment of  preservation solu-
tions is an up-and-coming approach for improving the 
preservation of  suboptimal liver grafts. 
Statins: Statins, or the 3-hydroxyl-3-methylglutaryl 
coenzyme A inhibitor family, are a group of  drugs known 
to decrease cholesterol levels and treat dyslipidemias[55]. 
They also have a variety of  anti-inflammatory, antioxidant 
and immunoregulatory effects[56,57] and they maintain the 
endothelial barrier by activation of  eNOS and subsequent 
production of  NO[58-60]. Due to their various effects, 
statins have been proposed as effective pharmacological 
agents against IRI in both normal and steatotic livers[61-63]. 
UW supplementation with simvastatin (a synthetic analog 
of  statin) prevented the deleterious effects of  cold 
storage in endothelial cells, due to the enhancement of  
vasoprotective pathways, thus improving liver viability[64]. 
With this in mind, the supplementation of  IGL-1 with 
simvastatin could promote the NO generation induced by 
IGL-1 solution alone, and may contribute to preventing 
the exacerbated microcirculation complications existing 
in fatty liver grafts after revascularization. In addition, 
increased levels of  NO could contribute to stabilize 
cytoprotective factors such as HIF-α, which are generated 
as an adaptive response to the hypoxic conditions that 
characterize cold preservation[30].
New potential additives: some considerations
Sirtuin activators: Sirtuin1 (SIRT1) is a deacetylase 
that regulates the activity of  various non-histone and 
histone proteins and as a result is involved in various 
cell processes such as apoptosis and oxidative stress[65-68]. 
SIRT1 induces AmpK activation through LKB1 
deacetylation, and favors NO production by e-NOS 
activation[69,70]. Further, in a recent study published by 
our group, we mentioned that SIRT1 is involved in the 
beneficial effects of  ischemic preconditioning, partly via 
AmpK and eNOS activation[68]. Consequently, addition 
of  SIRT1 activators in preservation solutions may be 
a promising strategy for prolonging storage periods; 
SIRT1 activators may activate AmpK and maintain the 
cell energy status, and may also increase NO levels and 
alleviate microcirculation disturbances, especially in fatty 
livers. preliminary data obtained from our laboratory 
showed that SIRT1 is a differential marker in steatotic 
and non-steatotic livers during cold preservation. Since 
SIRT1 activity requires high NAD+ levels, NAD+ 
activators may also contribute to better liver graft 
preservation by activating not only SIRT1, but also other 
members of  sirtuin-family such as Sirtuin3 (SIRT3). 
SIRT3 is located in the mitochondria and affects the 
acetylation status of  various mitochondrial proteins[71]. 
Enhancement of  SIRT3 activity could thus achieve better 
mitochondrial preservation and prevent reactive oxygen 
potential for use as an additive in commercial preservation 
solutions for clinical transplantation purposes. 
Hormones: melatonin (mL), a hormone produced by 
the pineal gland in a circadian manner, has been shown 
to be highly beneficial for enhancing resistance of  both 
steatotic and non-steatotic livers against IRI when added 
to IGL-1. mL decreased hepatic injury by overexpression 
of  endothelial NO synthase (e-NOS) and Heme Oxy-
genase-1, and reduced mitochondrial damage and 
oxidative stress[43]. These protective effects of  mL in 
fatty liver graft preservation were further potentiated by 
addition of  TmZ to IGL-1 + mL solution[38]. protective 
mechanisms were dependent on AmpK activation. 
Furthermore, UW and IGL-1 solutions enriched with 
trophic factors like epidermal growth factor and insulin-
like growth factor-1 enhanced the resistance of  steatotic 
livers to IRI, partly due to Akt and eNOS signaling 
activation, and reduced cytokine release[44-46].
Proteasome inhibitors: The ubiquitin proteasome 
system (UpS) is an energy-dependent system that degra-
des misfolded proteins and regulates various cellular 
processes[47]. It has been established that proteasome 
activation is a pathophysiologically relevant mechanism 
of  cold ischemic myocardial injury. A subset of  26S 
proteasomes appears to be a cell-destructive protease 
that is activated as ATp levels decline[48]. The addition 
to UW solution of  epoxomicin, a proteasome inhibitor, 
reduced cardiac edema and preserved the ultrastructural 
integrity of  the post-ischemic cardiomyocyte[49]. In liver, 
we have recently demonstrated that the addition of  the 
reversible UpS inhibitors bortezomib (BRZ) and mG132 
to UW solution improved steatotic and non-steatotic liver 
preservation, and that the protective effect of  BRZ was 
superior to that of  mG132[50]. Supplementation of  IGL-1 
solution with BRZ also showed protective effects which 
were partially mediated through the activation of  AmpK 
and Akt/mTOR signaling[51]. 
Carbonic anhydrase Ⅱ: Carbonic anhydrase (CA) are 
Zn-metalloenzymes that catalyze the reversible reaction 
between carbon dioxide hydration and bicarbonate 
dehydration. Recently the function of  CAs has aroused 
great interest, as they contribute to the transport of  
CO2 and protons across the biological membranes and 
are involved in pH regulation, CO2 homeostasis and 
biosynthetic reactions such as gluconeogenesis, lipo-
genesis and ureagenesis. In mammals 16 different 
CAs are found, with different amino acid sequences, 
enzymatic properties and sites of  expression[52]. Since 
carbonic anhydrase Ⅱ (CAⅡ) also contributes to 
acid-base homeostasis[53], we suggest that it could be 
modulated in conditions of  liver preservation and that its 
addition to the preservation solution could be an efficient 
strategy for reversing pH alterations provoked by cold 
ischemia. Indeed, in preliminary studies at our laboratory, 
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species (ROS) production during reperfusion. 
Nrf2 activators: moreover, recent studies have demon-
strated the importance of  Nrf2 in IRI models[72-74]. 
Nrf2 is activated under conditions of  oxidative stress 
and induces the transcription of  anti-oxidant enzymes 
in order to eliminate redox stress. Nrf2-deficient livers 
exhibit enhanced liver injury upon IRI[75]. Consequently, 
we propose the use of  Nrf2 activators in preservation 
solutions in order to alleviate oxidative stress during 
reperfusion.
All in all, extensive studies in experimental models 
have proposed modified preservation solutions in order 
to extend cold storage and to maintain graft viability 
as far as possible. Since IRI is a multifactorial process, 
preservation solutions could incorporate various 
pharmacological agents in order to combine diffe-rent 
protective mechanisms and thus improve liver pre-
servation. Nonetheless, the use of  pharmacological 
agents may be limited by their potential toxicity and side 
effects or their unsuitability for suboptimal grafts, and so 
novel strategies of  preservation should be developed. 
Liver graft wash out
After cold storage, the liver grafts preserved in com-
mercial preservation solutions need to be washed out to 
remove the solution before reperfusion and also to obtain 
the most suitable conditions for graft revascularization 
and viability after transplantation. Although research into 
rinse solutions is limited, recent data from our laboratory 
show that washing out the liver grafts preserved in UW 
for 24 h, with a rinse solution containing pEG35, is an 
effective tool for reducing liver graft injury after two 
hours of  ex vivo perfusion[76]. pEG35 in the rinse solution 
was associated with decreased oxidative stress and 
mitochondrial damage, increased activation of  AmpK, 
and enhanced NO generation. In addition, it contributed 
to restoring cytoskeleton integrity following IRI. In 
contrast, when livers were preserved in IGL-1 solution, 
these benefits were not evident, probably due to the 
presence of  pEG35 as oncotic agent (unpublished data).
It is well known that pEG molecules are water-
soluble polymers of  various molecular weights which 
are non-immunogenic and non-toxic[77]. In general, 
pEGs prevent the generation of  ROS[78,79], enhance cell 
survival pathways in hypoxia/reoxygenation conditions 
and repair endothelial cell damage during post-ischemic 
reperfusion[80,81]. pEG exerts its cytoprotective role 
through the restoration of  membrane integrity[15,78,81,82] 
or by entering the cell through the disrupted membranes 
and interacting with cellular organelles[83]. In hypothermic 
hepatocyte preservation, pEG8 (8 kDa) prevented cell 
swelling through a mechanism that was independent of  
its osmotic properties[14]. 
DYNAMIC PRESERVATION: MACHINE 
PERFUSION TECHNIQUES 
For standard liver grafts, SCS with different preservation 
solutions remains highly successful. However, with 
the increasing need for organs in recent years, the use 
of  novel techniques for optimizing suboptimal graft 
preservation is arousing interest. 
MP consists of  creating a controlled recirculating flow 
of  preservation solution through the organ using a pump. 
This continuous perfusion permits better penetration 
of  the preservation solution, a thorough washout of  
blood and equilibration of  the interstitium with the 
perfusate medium, delivery of  oxygen and nutrients 
(if  the perfusate is oxygenated), and removal of  toxic 
metabolites (when the perfusate is renewed or filtered). In 
addition, it allows real-time monitoring of  the functional 
and biochemical performance of  the graft and the 
provision of  metabolic support during preservation[84].
Unlike the kidney, the mp protocol for the liver is 
determined mainly by the temperature of  preservation: 
hypothermic (Hmp) at 4 ℃, normothermic (Nmp) at 
37 ℃ and subnormothermic (SNmp) at 20 ℃-25 ℃. 
Also, several flows and pressures (pulsatile or not), 
single or dual perfusion (hepatic artery and portal vein), 
oxygenation or non-oxygenation, and different mp 
solution compositions have been tested in various liver 
graft experimental models[85].
HMP
Hmp is a dynamic cold preservation method at 4 ℃ 
which ensures homogeneous and continuous supply 
of  metabolic substrates to the graft during the ex vivo 
period[86]. During Hmp, aerobic metabolism decreases but 
does not stop completely and the provision of  metabolic 
substrates allows the reduction of  the cellular insults seen 
during reperfusion. 
Hmp offers several advantages over SCS. Guarrera 
et al[87] were the first to compare HMP to SCS in human 
liver transplantation, and showed that Hmp improves 
graft function and attenuates classical biochemical 
markers of  liver preservation injury. Given the fact that 
ROS accumulation during ischemia can lead to signi-
ficant hepatocyte toxicity, Hmp has been shown to 
protect the rodent liver from ROS by a reduction in 
glutathione depletion and superoxide anion release when 
compared with SCS[88]. And in the case of  suboptimal 
livers, Bessems et al[89] showed that Hmp improved both 
hepatocellular and endothelial function while reducing 
damage in a diet-induced rat fatty liver model. 
In contrast to the kidney, in which successful Hmp 
does not necessarily depend upon oxygenation, oxy-
genated Hmp (HOpE) has been developed as a means 
of  improving the quality of  liver preservation in normal 
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or ECD livers[90]. Oxygenated preservation enables 
grafts to restore tissue homeostasis and to maintain the 
functional integrity of  hepatocytes during ischemia. 
In a recent study, Schlegel et al[91] also described a 
protective effect on the rodent biliary system using 
HOpE in DCD grafts that underwent transplantation. 
As expected, perfusion with the HOpE system decreased 
the parameters of  hepatocellular injury and lowered 
immunogenic upregulation. 
Perfusates for HMP: In general, the composition of  
perfusate solutions used for Hmp is based on a re-
formulation of  UW solution, in which lactobionate is 
replaced by gluconate. This solution, named Belzer-mp 
solution (Belzer-mpS), continues to be the predominant 
perfusion solution.
Bessems et al[92] described a new Hmp solution, 
polysol, which contains amino acids, histidine, glutamine, 
tryptophan, ascorbic acid and α-tocopherol. Their studies 
show that polysol improved liver preservation compared 
to Belzer’s mpS, with lower enzyme release and increased 
bile production. Vasosol has also been proposed as an 
efficient alternative for HMP[87]. Its composition is based 
on Belzer-mpS but it is supplemented with antioxidants 
(N-acetyl-cysteine), metabolic substrates (α-ketoglutarate, 
L-arginine) and vasodilators (prostaglandin E1 and 
nitroglycerin). Recently, the benefits of  Vasosol have been 
improved by the addition of  α-tocopherol to further 
enhance antioxidant properties when Hmp is used[93].
sNMP
Recently it has been suggested that the use of  SNmp 
systems may be suitable for ex vivo preservation and 
recovery of  human liver for transplantation. SNmp is 
an intermediate status for graft conservation, using sub-
thermic conditions (20 ℃-25 ℃), taking advantage of  the 
lower metabolic demand in sub-physiological temperature 
conditions, while still maintaining sufficient metabolism 
for viability testing and improvement of  graft function. 
SNmp has already proven advantageous in reducing 
markers of  biliary injury during preservation and in 
restoring normal biliary physiology[94]. A recent study by 
Bruinsma et al[95] is the first demonstration of  the capacity 
of  SNmp to sustain human livers. This group showed 
that SNmp effectively supports the human liver ex vivo 
with minimal injury, and normalizes physiological post-
ischemia disturbances.
NMP
The principle of  normothermic perfusion is the mainte-
nance of  normal cellular metabolism in a physio-logical 
environment throughout the preservation period by 
maintaining normal temperature (37 ℃) and providing 
oxygen and essential substrates[96]. This ensures large-
scale metabolic activity and the maintenance of  energy 
reserves such as ATp content. Nmp has the advantage of  
allowing viability assessment prior to transplantation. As 
the liver metabolism is maintained during preservation, 
markers including bile production and liver enzymes can 
be measured. 
Nmp is an emerging technology whose potential in 
liver preservation has been described in several animal 
studies, which have shown its superiority over SCS in the 
preservation of  liver grafts[96-98]. Interestingly, porcine and 
murine models of  DCD livers are significantly improved 
by Nmp compared to organs preserved by SCS[99,100]. 
Recently, Ravikumar et al[101] reported the first clinical 
trial of  transplanted livers with Nmp. Their study 
included 10 transplanted patients with relatively low risk 
donors and recipients, and showed that Nmp is safe and 
feasible in human applications. This study opens up new 
avenues for research into liver graft preservation with 
Nmp.
Recently, Nmp has emerged as a novel tool for 
decreasing steatosis in a process named “defatting”. In 
a preliminary study using porcine livers, ex vivo normo-
thermic perfusion for 48 h led to a 50% reduction in 
lipid droplet size in perivenous hepatocytes, reaching the 
size found in control lean livers[102]. moreover, Nmp of  
steatotic livers from Zucker ob rats using a “defatting 
cocktail” decreased the intracellular lipid content by 
50% over 3 h of  perfusion[103]. Decreasing steatosis 
prior to transplantation by short term Nmp would allow 
the transplantation of  severely steatotic livers and thus 
alleviate the donor liver shortage.
Perfusates for NMP: Nmp requires advanced metabolic 
support since the organ is fully metabolically active. 
Therefore, typically diluted blood-based perfusates are 
used. more recently, a solution initially described for lung 
perfusion has also been applied to liver grafts[104]. Steen is 
a buffered extracellular solution containing dextran and 
albumin at an optimized colloid osmotic pressure.
For defatting purposes, the perfusate developed 
contains different compounds to activate nuclear receptors 
such as ppARs, pregnane X receptor, and constitutive 
androstane receptor in order to exert an insulin-mimetic 
effect and to stimulate intracellular cAmp. This liquid 
was added into minimum Essential cell culture medium 
as a perfusate to stimulate the lipid metabolism of  
obese rat liver grafts preserved using Nmp. With this 
cocktail, a significant decrease (50%) in steatosis was 
observed after 3 h of  Nmp[103]. A recent study showed 
that the supplementation of  this cocktail with L-car-
nitine, together with hyperoxic exposure, abolished the 
sensitivity of  macrosteatotic hepatocytes to hypoxia 
reoxygenation (H/R)[105].
BIOENGINEERING IN LIVER GRAFT 
PRESERVATION
In the context of  liver graft preservation, bioengineered 
human livers represent an opportunity to test new 
solutions and liver preservation methods, thus potentially 
bypassing the requirement of  precious and scarce human 
organs. Bioengineering allows quicker and cheaper 
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development and transfer to the clinic[106].
Over the past few years, organ bioengineering has 
come of  age. The seminal study by Ott et al[107] in 2008 on 
heart decellularization and recellularization paved the way 
for whole organ bioengineering. After this initial study of  
the heart, many other organs followed. In 2009, Baptista 
et al[108] described the first methods for liver, pancreas 
and kidney decellularization and recellularization, and 
their paper was followed by an exponential growth of  
publications by many other authors. 
Currently, with several solid organs already successfully 
bioengineered and under further development by 
several groups around the world, this technology has 
huge potential. However, bioengineered organs are still 
not available to the transplant surgeon as alternative 
grafts. There are already several applications that can 
be addressed and extended with the current generation 
of  bioengineered organs and their acellular scaffolds. 
most of  these applications, like drug metabolism[106], 
organ/tissue physiology[106,107,109,110], matrix biology[111], 
developmental biology[111,112], and stem cell biology[113] are 
perfectly complemented by these novel bioengineered 
human tissues which will open up exciting new experi-
mental avenues. 
In the particular context of  normothermic perfusion, 
the enabling bioreactor and culture media technology 
developed in the bioengineering process of  livers may 
constitute a new body of  knowledge that can help 
further the development of  Nmp for liver preservation, 
due to the similarities of  the conditions used[114]. Finally, 
the use of  normothermic perfusion bioreactors in 
liver preservation and bioengineered human livers may 
also provide a better route and environment for ex vivo 
administration of  mesenchymal stem cells. The use of  
these cells has been proposed as a novel way to attenuate 
IRI and to downregulate the alloimmune response 
(adaptive immunity) and promotes engraftment after 
transplantation[115]. This has been demonstrated for rat 
kidneys, thus raising the hope that it may also work in the 
liver and other solid organs[116].
CONCLUSION
Due to its low cost and simple technical and logistical 
requirements, SCS is still preferred to mp as the standard 
method of  preservation in liver transplantation. SCS 
is probably unsuitable for suboptimal liver grafts, 
because they have already suffered severe tissue damage 
secondary to hypoxia during the initial period of  warm 
ischemia. Additional damage to the organ due to 
hypothermic conditions may limit the ability to restore 
cellular function, because metabolic activity is decreased 
at low temperatures. 
The growing need to use suboptimal livers and 
to expand donor pool is accompanied by the drive to 
improve current preservation techniques before trans-
plantation. In this situation, there has been renewed 
interest in liver graft preservation using machine per-
fusion. Both Hmp and Nmp have been found to be 
beneficial in preserving normal and suboptimal livers, 
and their relative merits are currently being debated. 
more basic research and randomized controlled trials are 
needed. As for SNmp preservation, it remains relatively 
unexplored at present. 
Studies on the cost-effectiveness of  mp and SCS will 
continue over the coming years, but considerable support 
for mp is beginning to emerge. Table 2 summarizes its 
advantages and disadvantages for liver preservation. It 
seems clear that mp strategies will play an increasing role 
and that their use should be optimized, including the 
subsequent development of  new perfusion solutions. 
With this in mind, the future of  liver mp preservation 
will also depend on the composition of  perfusion 
solutions. At present, little attention is being paid to the 
potential advantages of  adding cytoprotective, immuno-
modulating, pro-regenerative components to the mp 
solutions. 
It is well known that pEG protects cell membranes; it 
has already been used as a colloid in machine perfusion, 
just as it was previously in SCS. The development of  
different pEG molecules could establish new frontiers 
in the design of  new perfusion solutions for application 
in mp techniques and may increase graft conservation in 
the future. The revitalization of  steatotic livers through 
defatting agents represents another interesting future 
application, given that the worldwide incidence of  
severely steatotic livers is expected to rise together with 
the increase in obesity rates.
Finally, bioengineering is another area with great 
potential for graft preservation in clinical transplantation.
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